Published in JAMA on September 16, 2009
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol (2015) 4.72
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol (2012) 2.28
Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys (2014) 2.06
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol (2012) 1.65
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer. Cancer (2014) 1.55
Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol (2012) 1.54
Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst (2012) 1.50
Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care. Med Care (2014) 1.50
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol (2015) 1.44
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases. Br J Cancer (2010) 1.11
Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr (2012) 1.11
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab (2012) 1.08
Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis (2012) 1.06
Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys (2012) 1.05
Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol (2012) 1.04
Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res (2012) 1.03
Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med (2012) 0.98
Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol (2010) 0.96
The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. Prostate Cancer Prostatic Dis (2011) 0.93
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Screening for prostate cancer: early detection or overdetection? Annu Rev Med (2011) 0.92
Active surveillance: the Canadian experience with an "inclusive approach". J Natl Cancer Inst Monogr (2012) 0.92
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS One (2014) 0.89
Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer (2013) 0.88
Increasing use of observation among men at low risk for prostate cancer mortality. J Urol (2014) 0.88
Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California. Open Prost Cancer J (2013) 0.87
Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J (2013) 0.87
Variation in quality of care among older men with localized prostate cancer. Cancer (2010) 0.86
Limitations of a contemporary prostate biopsy: the blind march forward. Urol Oncol (2010) 0.86
SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation. Cancer Res (2015) 0.86
Life-Threatening Disparities: The Treatment of Black and White Cancer Patients. J Soc Issues (2012) 0.85
The impact of technology diffusion on treatment for prostate cancer. Med Care (2013) 0.85
Quality of life in patients with low-risk prostate cancer. A comparative retrospective study: brachytherapy versus robot-assisted laparoscopic prostatectomy versus active surveillance. J Endourol (2013) 0.84
The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. Clin Cancer Res (2014) 0.84
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
A Bayesian nonrigid registration method to enhance intraoperative target definition in image-guided prostate procedures through uncertainty characterization. Med Phys (2012) 0.83
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines. PLoS One (2014) 0.83
Novel therapies for the treatment of advanced prostate cancer. Curr Treat Options Oncol (2013) 0.82
Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last? J Urol (2012) 0.81
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch (2014) 0.81
Challenging treatment decision-making in older urologic cancer patients. World J Urol (2013) 0.81
Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality. BMC Urol (2014) 0.80
Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer. Sci Rep (2015) 0.80
Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int (2015) 0.79
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2015) 0.79
Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. Ann Epidemiol (2010) 0.79
Optimizing the management of high-risk, localized prostate cancer. Korean J Urol (2012) 0.79
Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomes. Patient Relat Outcome Meas (2015) 0.78
Age and prostate cancer survival. JAMA (2010) 0.78
Our results of active surveillance for localized prostate cancer patients. Turk J Urol (2013) 0.78
Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU Int (2015) 0.78
Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res (2014) 0.78
The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer. Oncotarget (2016) 0.77
Focal therapy, differential therapy, and radiation treatment for prostate cancer. Adv Urol (2012) 0.77
The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clin Genitourin Cancer (2014) 0.77
Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. Urology (2014) 0.76
Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. Urol Oncol (2017) 0.75
Five-year follow-up of active surveillance for prostate cancer: A Canadian community-based urological experience. Can Urol Assoc J (2014) 0.75
Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida. Am J Mens Health (2013) 0.75
Diagnosis of localized, screen-detected, prostate cancer--crisis or opportunity? J Natl Cancer Inst (2010) 0.75
Screening and efficacy of radical prostatectomy. Asian J Androl (2013) 0.75
Response. J Natl Cancer Inst (2014) 0.75
Overall rate, location, and predictive factors for positive surgical margins after robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer. Asian J Androl (2015) 0.75
External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence. Asian J Androl (2011) 0.75
Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: No. Int Braz J Urol (2016) 0.75
The context of prostate cancer genomics in personalized medicine. Oncol Lett (2017) 0.75
You're kidding...I have cancer? A patient's perspective on coping with prostate cancer and why active surveillance was not chosen. J Natl Cancer Inst Monogr (2012) 0.75
Prostate MRI: a national survey of Urologist's attitudes and perceptions. Int Braz J Urol (2016) 0.75
Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. PLoS One (2015) 0.75
What is the risk posed by prostate cancer? J Natl Cancer Inst Monogr (2012) 0.75
Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan. Cancer Sci (2017) 0.75
Active Surveillance for Intermediate Risk Prostate Cancer. Curr Urol Rep (2017) 0.75
A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center. World J Urol (2014) 0.75
Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer Prostatic Dis (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Development of a comorbidity index using physician claims data. J Clin Epidemiol (2000) 19.31
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Tutorial in biostatistics: competing risks and multi-state models. Stat Med (2007) 10.61
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med (2008) 6.02
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Utility of the SEER-Medicare data to identify chemotherapy use. Med Care (2002) 5.07
Results of conservative management of clinically localized prostate cancer. N Engl J Med (1994) 5.04
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA (1992) 4.31
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet (1997) 3.84
Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
Hazard rate estimation under random censoring with varying kernels and bandwidths. Biometrics (1994) 3.12
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol (2004) 2.53
Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst (2001) 2.46
A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol (2000) 2.18
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Early outcomes of active surveillance for localized prostate cancer. BJU Int (2005) 1.84
Recent results of management of palpable clinically localized prostate cancer. Cancer (1993) 1.78
Clinical practice. Localized prostate cancer. N Engl J Med (2007) 1.72
Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol (2008) 1.28
Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it? Semin Radiat Oncol (2008) 1.16
Deferred treatment in clinically localised prostatic carcinoma. Br J Urol (1992) 1.00
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2011) 9.75
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2014) 8.74
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
The double-edged sword of autophagy modulation in cancer. Clin Cancer Res (2009) 5.46
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. N Engl J Med (2015) 4.58
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Defining patient complexity from the primary care physician's perspective: a cohort study. Ann Intern Med (2011) 3.83
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Screening for prostate cancer--the controversy that refuses to die. N Engl J Med (2009) 3.59
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Video decision support tool for advance care planning in dementia: randomised controlled trial. BMJ (2009) 3.55
Tumorigenic effect of some commonly used moisturizing creams when applied topically to UVB-pretreated high-risk mice. J Invest Dermatol (2008) 3.44
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst (2007) 3.07
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer (2002) 3.05
How patient centered are medical decisions?: Results of a national survey. JAMA Intern Med (2013) 3.02
Do patient decision aids meet effectiveness criteria of the international patient decision aid standards collaboration? A systematic review and meta-analysis. Med Decis Making (2007) 3.02
Patient-physician connectedness and quality of primary care. Ann Intern Med (2009) 3.01
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer (2002) 2.90
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med (2009) 2.82
The economic impact of chronic prostatitis. Arch Intern Med (2004) 2.74
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol (2011) 2.69
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med (2008) 2.66
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst (2002) 2.54
Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53
Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med (2004) 2.44
Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol (2003) 2.40
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology (2008) 2.12
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int (2013) 2.10
Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2013) 2.05
A mixture model for estimating the local false discovery rate in DNA microarray analysis. Bioinformatics (2004) 2.03
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol (2009) 2.00
Relationship between patient panel characteristics and primary care physician clinical performance rankings. JAMA (2010) 1.95
Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens (2006) 1.95
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol (2003) 1.88
Analyzing excessive no changes in clinical trials with clustered data. Biometrics (2004) 1.87
The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol (2010) 1.87
Lack of comprehension of common prostate cancer terms in an underserved population. J Clin Oncol (2009) 1.82
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol (2011) 1.75
The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep (2003) 1.73
United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology (2002) 1.73
Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res (2005) 1.72
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg (2005) 1.66
Is this "my" patient? Development and validation of a predictive model to link patients to primary care providers. J Gen Intern Med (2006) 1.66
High quality care and ethical pay-for-performance: a Society of General Internal Medicine policy analysis. J Gen Intern Med (2009) 1.65
Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys (2003) 1.65
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer (2008) 1.63
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Decision-making processes for breast, colorectal, and prostate cancer screening: the DECISIONS survey. Med Decis Making (2010) 1.61
Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol (2002) 1.61